How to Get Jatenzo in Alaska: Telehealth, Prescriptions, and Pharmacy Guide

What Is Jatenzo and Why Does It Require a Special Prescribing Approach?

Jatenzo is the first FDA-approved oral testosterone replacement therapy for adult males with hypogonadism caused by certain medical conditions. Because testosterone is a Schedule III controlled substance under the Controlled Substances Act, prescribers must follow DEA registration requirements and state-specific rules on top of standard prescribing practice. Alaska permits telehealth-initiated controlled substance prescriptions once a valid prescriber-patient relationship is established, making remote access feasible for most residents.

The active ingredient, testosterone undecanoate, is absorbed through intestinal lymphatic transport rather than first-pass hepatic metabolism, which differentiates it pharmacokinetically from older oral androgen formulations [1]. The FDA approved Jatenzo in March 2019 based on the key Phase III trial by Swerdloff et al., published in the Journal of Clinical Endocrinology and Metabolism, in which 87% of 166 evaluable men achieved average testosterone concentrations within the normal range (300 to 1 to 000 ng/dL) after dose titration over 16 weeks [2]. Mean total testosterone on the starting dose of 237 mg twice daily was 462 ng/dL; after titration it reached 520 ng/dL in the per-protocol population [2].

Jatenzo carries a boxed warning for blood pressure increases. In the Swerdloff trial, mean systolic blood pressure rose by 3.9 mmHg from baseline, and 24% of participants required initiation or intensification of antihypertensive therapy [2]. Any Alaska provider initiating Jatenzo must document baseline blood pressure and monitor it at each titration visit, per the FDA-approved prescribing information [1].

Alaska's geography means that roughly 60% of the state's 733,000 residents live more than 50 miles from an endocrinologist or urologist. Telehealth-capable TRT providers fill that gap directly.

Alaska Telehealth Rules for Controlled Substance Prescribing

Alaska allows synchronous audio-video telehealth visits to establish the prescriber-patient relationship required before issuing a Schedule III controlled substance prescription. Alaska Statute 08.64.107 and Alaska Administrative Code 12 AAC 40.985 govern telemedicine practice for physicians; parallel provisions apply to advanced practice providers. The prescriber must hold an active Alaska license and a DEA registration listing Alaska as a registered state.

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 ordinarily requires an in-person evaluation before a practitioner may prescribe a controlled substance via the internet [3]. A DEA telemedicine exception, codified under 21 U.S.C. § 831, permits audio-video prescribing when the patient is treated by and physically located at a DEA-registered hospital or clinic. As of 2025, the DEA's proposed Special Registration framework for telemedicine prescribing of controlled substances remains under federal rulemaking, so patients should confirm their chosen platform's current compliance posture before booking [3].

Practically, most reputable telehealth TRT platforms operating in Alaska conduct a live video visit, collect uploaded lab results, and transmit the Jatenzo prescription electronically to a retail or mail-order pharmacy licensed in Alaska. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states that "testosterone therapy should be prescribed only to men who have unequivocally low serum testosterone concentrations and symptoms or signs of androgen deficiency" [4]. That standard applies whether the visit is in-person or via video.

Labs Required Before a Provider Can Prescribe Jatenzo in Alaska

Getting labs drawn before your telehealth consult cuts the time to prescription by two to four days. Most Alaska providers require the same core panel.

Mandatory baseline labs:

• Total testosterone, drawn between 7 AM and 10 AM on two separate mornings (two low values confirm hypogonadism per Endocrine Society guidelines [4])
• Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to classify primary versus secondary hypogonadism
• Complete blood count (CBC) with hematocrit, because testosterone stimulates erythropoiesis and Jatenzo's label flags polycythemia risk [1]
• Comprehensive metabolic panel (CMP) for hepatic and renal baseline
• Prostate-specific antigen (PSA) in men 40 and older, or in any man with a first-degree relative with prostate cancer
• Blood pressure measured at visit; home readings for 7 days prior are acceptable documentation

Commonly added labs:

• Free testosterone (calculated or equilibrium dialysis) when total testosterone is borderline (270 to 350 ng/dL)
• Estradiol (E2) by LC-MS/MS if gynecomastia or mood symptoms are present
• HbA1c and fasting lipid panel, given testosterone's effect on insulin sensitivity and HDL [5]

Quest Diagnostics and LabCorp both operate patient service centers in Anchorage, Fairbanks, and Juneau. Residents in rural areas may use the Alaska Native Tribal Health Consortium laboratory network or arrange specimen transport through providers such as PAML (Pacific Alliance Medical Laboratories), which ships samples from remote communities to processing facilities [6].

The American Urological Association's 2018 guideline on testosterone deficiency specifies that "in a patient with symptoms and signs of testosterone deficiency, laboratory evaluation should include two morning total testosterone measurements" [7]. A single low value is not sufficient to initiate therapy.

How to Get a Jatenzo Prescription in Alaska: Step-by-Step

Step 1. Collect labs. Order the panel above through your primary care provider, a direct-access lab order, or a telehealth platform's standing lab requisition. Morning draws on two separate days are required.

Step 2. Choose a licensed Alaska prescriber. Options include an endocrinologist, urologist, or men's health telehealth service holding an Alaska DEA registration. Confirm the provider is licensed with the Alaska State Medical Board (searchable at commerce.alaska.gov).

Step 3. Complete a synchronous video or in-person visit. The provider reviews your labs, assesses symptoms using a validated tool such as the Androgen Deficiency in Aging Males (ADAM) questionnaire, measures or reviews blood pressure, and documents the hypogonadism diagnosis using ICD-10 code E29.1 (testicular hypofunction) or E23.0 (hypopituitarism) as appropriate.

Step 4. Receive the electronic prescription. The prescriber transmits the Jatenzo Rx to your designated pharmacy. Because testosterone is Schedule III, Alaska law requires a written or electronic prescription; telephone orders for Schedule III substances are permitted for up to a 30-day supply, but most pharmacies prefer electronic submission.

Step 5. Initiate therapy and monitor. The FDA label recommends measuring testosterone 3 to 5 hours post-dose (Cmax window) at the 3-to-6-week titration visit [1]. If Cavg falls below 300 ng/dL, increase the dose one step. If it exceeds 1 to 050 ng/dL, decrease one step. Blood pressure must be checked at every titration visit [1].

Jatenzo Dosing and Titration Protocol

Jatenzo is dispensed as three capsule strengths: 158 mg, 198 mg, and 237 mg of testosterone undecanoate. All doses are taken twice daily with food; the lymphatic absorption mechanism requires dietary fat for adequate bioavailability [2].

Standard titration ladder:

| Step | Dose per administration | Total daily dose | |------|------------------------|-----------------| | Start | 237 mg twice daily | 474 mg/day | | Decrease | 198 mg twice daily | 396 mg/day | | Decrease further | 158 mg twice daily | 316 mg/day | | Increase from start | Not applicable; 237 mg is the ceiling |, |

The Swerdloff Phase III trial demonstrated that 87% of men reached the 300 to 1 to 000 ng/dL target range after titration, with a median time to first titration of 42 days [2]. Men whose testosterone remained below 300 ng/dL on the starting dose were a minority; most required a dose decrease due to supratherapeutic levels rather than an increase, underscoring the importance of the week-3-to-6 monitoring draw.

Patients should take each dose with a meal containing at least 15 grams of fat. Taking Jatenzo in the fasted state reduces Cmax by approximately 40% based on pharmacokinetic data from the label [1]. A standard breakfast or lunch is sufficient; the meal does not need to be high-fat.

Prior Authorization Requirements in Alaska

Alaska Medicaid does not cover Jatenzo for male hypogonadism, which eliminates Medicaid prior authorization (PA) as a pathway. For patients with commercial insurance, PA requirements vary by plan but commonly include:

• Two documented morning total testosterone values below the lab's reference range (typically <300 ng/dL)
• Confirmed diagnosis code (E29.1 or E23.0) with clinical notes
• Documentation that the patient either failed or is not a candidate for generic injectable testosterone cypionate or enanthate (which cost roughly $30 to $80 per month versus $400 to $600 per month for Jatenzo)
• Blood pressure at or below 160/100 mmHg at the time of prescribing (reflecting the boxed warning)
• PSA below 4.0 ng/mL or documented urological clearance if PSA is elevated

The Endocrine Society guideline notes that "clinicians should prescribe testosterone therapy for men with hypogonadism to induce and maintain secondary sex characteristics and to improve their sexual function, sense of well-being, and bone mineral density" [4]. Quoting this directly in the PA letter, alongside the specific clinical scenario supporting oral formulation (patient intolerance of injections, needle phobia, or occupation-related skin-contact concerns precluding gels), strengthens approvals.

Tolmar offers the Jatenzo Savings Program for commercially insured patients, which may reduce out-of-pocket cost to as low as $0 per month for eligible patients. Uninsured patients can access the manufacturer patient assistance program; the prescribing office or a telehealth platform's pharmacy concierge typically submits this paperwork on the patient's behalf.

Pharmacy Options for Jatenzo in Alaska

Retail pharmacies. Major chains including Walgreens, Safeway Pharmacy, and Fred Meyer Pharmacy (Kroger) in Anchorage and Fairbanks stock or can order Jatenzo within one to three business days. Smaller communities may require a special order. Costco Pharmacy in Anchorage consistently carries branded testosterone products.

Mail-order pharmacies. Optum Rx, CVS Caremark, and Express Scripts each ship to Alaska addresses. Standard mail-order (90-day supply) requires the prescriber to issue the full 90-day prescription at the time of writing; controlled substance regulations in Alaska permit a 90-day supply for Schedule III when issued at the time of the original prescription. Shipping to rural Alaska addresses via USPS Priority Mail typically takes three to five business days from the lower-48 fulfillment center.

503A compounding pharmacies. A 503A compounding pharmacy licensed in Alaska may prepare oral testosterone undecanoate capsules for a specific patient when the prescriber documents a clinical rationale for compounding over the commercially available product. The FDA's guidance on compounding distinguishes 503A pharmacies (patient-specific, requires valid prescription) from 503B outsourcing facilities [8]. Alaska's Board of Pharmacy regulates 503A pharmacies operating in-state; out-of-state 503A pharmacies may ship to Alaska patients if licensed as a non-resident pharmacy with the Alaska Board of Pharmacy. Compounded oral testosterone undecanoate is not FDA-approved and lacks the bioavailability data of the Tolmar formulation, a point prescribers should document in the chart.

Specialty pharmacies. Amber Specialty Pharmacy and Maxor Specialty each have Alaska contracting and handle the PA process for Jatenzo on behalf of the prescriber's office.

Transferring an Existing Jatenzo Prescription to Alaska

Patients relocating to Alaska with an active Jatenzo prescription face a two-step process. Alaska law follows federal Schedule III rules: a prescription may be transferred between pharmacies once (for a Schedule III controlled substance). The receiving pharmacy must verify the original prescription with the dispensing pharmacy directly. After one transfer, a new prescription from an Alaska-licensed provider is required.

Practically, the cleanest path is to contact a telehealth TRT provider licensed in Alaska before or shortly after your arrival, upload existing lab results (which remain clinically valid for 6 to 12 months depending on the lab value), and obtain a new Alaska prescription at the telehealth visit. The DEA's Practitioner's Manual outlines transfer rules for Schedule III through V prescriptions [9]. Providers reviewing a prior-state chart can typically issue a bridge prescription the same day as the video visit if labs are current.

Blood Pressure Monitoring: A Non-Negotiable Requirement in Alaska

The Jatenzo boxed warning on blood pressure elevation is clinically significant and operationally relevant for Alaska patients who may lack easy access to frequent in-office monitoring. The FDA label requires blood pressure assessment "prior to initiating, following dose adjustments, and periodically during treatment" [1].

Remote blood pressure monitoring is a practical solution. A validated home sphygmomanometer (upper-arm cuff, validated by the American Heart Association criteria) used morning and evening for 7-day periods generates data equivalent to an office measurement series for titration purposes [10]. Patients should log readings in a format they can share via the telehealth portal (photograph of log, structured PDF, or connected device upload).

If systolic blood pressure rises above 160 mmHg or diastolic above 100 mmHg after initiating Jatenzo, the prescriber should pause therapy and evaluate before continuing. A 2020 meta-analysis of testosterone therapy and cardiovascular risk published in the Journal of Clinical Endocrinology and Metabolism found a modest mean systolic increase of 3 to 5 mmHg across oral and injectable testosterone formulations, consistent with the Jatenzo trial data [11]. Men with baseline blood pressure between 130/80 and 160/100 mmHg are candidates for Jatenzo with close monitoring; those above 160/100 mmHg should achieve blood pressure control before initiating oral testosterone.

Monitoring Schedule After Starting Jatenzo in Alaska

The following schedule reflects the FDA label requirements combined with Endocrine Society guideline recommendations [1][4]:

Week 3 to 6: Testosterone level drawn 3 to 5 hours after the morning dose (Cmax check). Blood pressure measured. Symptom review. Dose adjustment if indicated.

Month 3: Repeat testosterone (Cmax and trough), CBC with hematocrit, blood pressure. PSA if baseline was obtained. Lipid panel if not drawn at baseline.

Month 6: Full panel repeat. If hematocrit exceeds 54%, hold therapy and evaluate for secondary polycythemia per the Endocrine Society guideline recommendation to "withhold testosterone therapy until the hematocrit decreases to a safe level" [4].

Annually thereafter: Full panel plus bone mineral density (DEXA) if osteoporosis risk factors are present, digital rectal exam and PSA per AUA guideline in men 40 and older [7].

Telehealth platforms serving Alaska should provide standing lab orders through Quest or LabCorp that the patient can fulfill at any patient service center or mobile draw site, including Alaska Native health facilities.

Who Can Prescribe Jatenzo in Alaska

Alaska permits the following licensed practitioners to prescribe Schedule III controlled substances, including testosterone:

• Physicians (MD, DO) with active Alaska Medical Board license and DEA registration
• Advanced Practice Registered Nurses (APRNs) with prescriptive authority granted by the Alaska Board of Nursing; APRNs in Alaska may prescribe Schedule III substances independently without physician oversight under AS 08.68.265
• Physician Assistants (PA-C) under AS 08.64.107, with prescriptive authority; PA controlled substance prescribing in Alaska requires a supervising physician agreement for Schedule II substances but not for Schedule III

Naturopathic doctors (NDs) in Alaska hold limited prescriptive authority and are not authorized to prescribe controlled substances. Chiropractors and acupuncturists do not have prescriptive authority for Schedule III substances in Alaska.

For telehealth specifically, the prescriber's DEA registration must list Alaska or be a national DEA registration. A provider licensed only in California, for example, cannot prescribe a controlled substance to an Alaska resident patient, regardless of the telehealth platform used.